Several brokerages have updated their recommendations and price targets on shares of Amgen (NASDAQ: AMGN) in the last few weeks:
- 7/27/2017 - Amgen had its price target raised by analysts at Argus from $180.00 to $195.00. They now have a “buy” rating on the stock.
- 7/26/2017 - Amgen had its “buy” rating reaffirmed by analysts at Cann. They now have a $203.00 price target on the stock, up previously from $189.00. They wrote, “Amgen reported GAAP earnings per share of $2.91, which is 3.2% higher than our estimate of $2.83. Earnings exceeded our expectations due to higher than estimated product sales and a lower than estimated tax rate. Higher than estimated product sales were primarily driven by higher sales of Aranesp, Kyprolis, Blincyto, and Sensipar. Nearly all of Amgen’s products exceeded our estimates for International sales. Total product sales of $5.57 billion exceeded our estimated $5.47 billion by 1.8% and exceeded consensus product sales by 2.7%.””
- 7/26/2017 - Amgen had its “hold” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $174.00 price target on the stock, up previously from $172.00.
- 7/26/2017 - Amgen had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $203.00 price target on the stock, up previously from $189.00.
- 7/26/2017 - Amgen was downgraded by analysts at BMO Capital Markets from an “outperform” rating to a “market perform” rating.
- 7/26/2017 - Amgen was given a new $180.00 price target on by analysts at UBS AG. They now have a “hold” rating on the stock.
- 7/22/2017 - Amgen had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $209.00 price target on the stock.
- 7/21/2017 - Amgen was downgraded by analysts at BMO Capital Markets from an “outperform” rating to a “market perform” rating. They now have a $199.00 price target on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.
- 7/17/2017 - Amgen had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $195.00 price target on the stock.
- 7/14/2017 - Amgen was given a new $177.00 price target on by analysts at Credit Suisse Group. They now have a “hold” rating on the stock.
- 7/14/2017 - Amgen had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $189.00 price target on the stock.
- 7/11/2017 - Amgen had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $195.00 price target on the stock.
- 7/10/2017 - Amgen had its “overweight” rating reaffirmed by analysts at Morgan Stanley.
- 7/9/2017 - Amgen had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $195.00 price target on the stock.
- 7/6/2017 - Amgen was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
- 6/30/2017 - Amgen had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $189.00 price target on the stock.
- 6/26/2017 - Amgen had its “market perform” rating reaffirmed by analysts at William Blair.
- 6/23/2017 - Amgen was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
- 6/23/2017 - Amgen is now covered by analysts at Deutsche Bank AG. They set a “hold” rating and a $172.00 price target on the stock.
- 6/22/2017 - Amgen had its “market perform” rating reaffirmed by analysts at Leerink Swann. They now have a $161.00 price target on the stock.
- 6/13/2017 - Amgen had its price target raised by analysts at Morgan Stanley from $183.00 to $184.00. They now have an “overweight” rating on the stock.
- 6/13/2017 - Amgen was given a new $189.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
- 6/13/2017 - Amgen had its “neutral” rating reaffirmed by analysts at UBS AG. They now have a $175.00 price target on the stock, up previously from $174.00.
- 6/8/2017 - Amgen was given a new $164.00 price target on by analysts at Sanford C. Bernstein. They now have a “hold” rating on the stock.
- 6/5/2017 - Amgen was given a new $189.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
- 6/2/2017 - Amgen was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
Shares of Amgen Inc. (AMGN) traded up 0.81% on Friday, reaching $173.54. 1,066,042 shares of the company were exchanged. The company has a market cap of $127.62 billion, a price-to-earnings ratio of 16.48 and a beta of 1.36. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $184.21. The company’s 50-day moving average price is $172.14 and its 200 day moving average price is $166.19.
Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. The business had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.84 EPS. On average, equities research analysts expect that Amgen Inc. will post $12.57 EPS for the current year.
In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the stock in a transaction that occurred on Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the sale, the senior vice president now owns 24,214 shares of the company’s stock, valued at approximately $3,738,641.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.20% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc and related companies with MarketBeat.com's FREE daily email newsletter.
